Precigen (PGEN) EBITDA (2012 - 2026)
Precigen (PGEN) reported EBITDA of -$6.0 million for Q1 2026, up 73.47% year-over-year from -$3.5 million in Q1 2025, and up 72.33% quarter-over-quarter from -$21.7 million in Q4 2025.
Precigen (PGEN) EBITDA (2012 - 2026) Analysis & Trends
Precigen (PGEN) has 15 years of EBITDA data on file, last reported at -$6.0 million in Q1 2026.
- EBITDA for Q1 2026 came in at -$6.0 million, up 73.47% year-over-year; the trailing twelve-month figure through Mar 2026 was -$93.9 million (up 29.51% YoY), and the FY2025 annual result was -$110.5 million, up 18.16% from the prior year.
- EBITDA grew to -$6.0 million in Q1 2026 per PGEN's latest filing, from -$21.7 million in the prior quarter.
- Over five years, EBITDA peaked at -$6.0 million in Q1 2026 and troughed at -$60.8 million in Q2 2024.
- A 5-year average of -$25.1 million and a median of -$22.6 million in 2025 frame the typical range for EBITDA.
- The sharpest annual moves came in 2024 and 2026: EBITDA plunged 188.07% in 2024, then soared 73.47% in 2026.
- A 5-year view of EBITDA shows it stood at -$21.8 million in 2022, then plunged by 57.01% to -$34.2 million in 2023, then increased by 16.68% to -$28.5 million in 2024, then gained by 24.02% to -$21.7 million in 2025, then surged by 72.33% to -$6.0 million in 2026.
- Business Quant data shows PGEN's EBITDA at -$6.0 million in Q1 2026, -$21.7 million in Q4 2025, and -$34.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | -26.92 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -13.63 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -14.44 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | -3.82 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | -752,618.00 |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -65.83 Mn |
| 10 | Precigen | 1.27 Bn | 1.27 Bn | 20.69 Mn | -5.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.99 Mn |
| Dec 31, 2025 | -21.67 Mn |
| Sep 30, 2025 | -34.48 Mn |
| Jun 30, 2025 | -31.76 Mn |
| Mar 31, 2025 | -22.60 Mn |
| Dec 31, 2024 | -28.52 Mn |
| Sep 30, 2024 | -21.26 Mn |
| Jun 30, 2024 | -60.84 Mn |
| Mar 31, 2024 | -24.41 Mn |
| Dec 31, 2023 | -34.22 Mn |
| Sep 30, 2023 | -20.94 Mn |
| Jun 30, 2023 | -21.12 Mn |
| Mar 31, 2023 | -23.48 Mn |
| Dec 31, 2022 | -21.80 Mn |
| Sep 30, 2022 | -7.61 Mn |
| Jun 30, 2022 | -24.16 Mn |
| Mar 31, 2022 | -22.15 Mn |
| Dec 31, 2021 | -21.87 Mn |
| Sep 30, 2021 | -21.53 Mn |
| Jun 30, 2021 | -26.22 Mn |